Metastatic colorectal cancer
Conditions
Interventions
Treatment Group:None
Sponsors
Danyang People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1) Visit from January 1st, 2023 to December 31st, 2023; 2) Age = 18 years old; 3) Patients with metastatic colorectal cancer confirmed by histology or cytology; 4) Indications for the use of bevacizumab according to clinical diagnosis and treatment conventions; 5) ECOG score 0-1 points; 6) Accept a treatment regimen containing bevacizumab in combination with chemotherapy, radiation therapy, immunization, etc.
Exclusion criteria
Exclusion criteria: 1) Patients with concomitant malignant tumors; 2) Individuals who are allergic to bevacizumab and its excipients; 3) Individuals with severe damage to the liver, kidneys, hematopoiesis, and cardiovascular system; 4) Pregnant or lactating women; 5) Patients with previous gastrointestinal perforation and fistula, including gallbladder perforation; Those who have undergone major surgery within 4 weeks before administration or whose wounds have not fully healed within 4 weeks before administration; 6) Patients with tumor infiltration into large blood vessels or proximal tracheal and bronchial networks, or recent occurrence of pulmonary hemorrhage/hemoptysis (>1/2 teaspoon of fresh red blood), or other risks of major bleeding; 7) Researchers believe that other conditions that are not suitable for treatment, such as active tuberculosis, cardiovascular accidents, cerebrovascular accidents, drug use, alcoholism, and other bad habits.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression free survival;Objective relief rate;Describe the number and proportion of users of bevacizumab combined with chemotherapy/radiotherapy/immunization; | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse reaction incidence rate;Types and severity of adverse reactions; | — |
Countries
China
Contacts
Public ContactLifang DING
Danyang People's Hospital
Outcome results
None listed